Related Experiment Video
Updated: Aug 17, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
[Pharmacologic intervention for vascular calcification]
Hiroko Segawa1, Junya Furutani, Ken-ichi Miyamoto
1Department of Molecular Nutrition Institution of Health Biosciences, The University of Tokushima Graduate School.
Abstract:
In patients with chronic renal insufficiency and dialysis, phosphate retention is a major factor in the development of vascular calcification. Prevention of phosphate retention with dietary and pharmacological means may prevent vascular calcification. Current therapy for hyperphosphatemia includes the administration of phosphate binders such as calcium carbonate (or calcium acetate), ammonium-based compounds, and phosphate-binding polymers (Renagel; sevelamer hydrochloride). However, it is difficult to administrate present phosphate binders to patients because of hypocalcaemia, outright toxicity, and constipation as its side effect. It is needed to development new drugs having fewer side effects and better compliance.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Venous Thrombosis III: Interprofessional Care